News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease
Mike Thompson/LinkedIn
Oct 27, 2024, 17:41

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared on X:

“S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease to direct Therapy Duration (DRAMMATIC) – Amrita Krishnan, Hoering, Phari, Sexton, Robert Z. Orlowski.

ASH20 Abstract 1515

1515 Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton, Robert Z. Orlowski

Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease

Amrita Krishnan Antje Hoering cancer Mike Thompson Myeloma OncoDaily Oncology Parameswaran Hari Rachael Sexton Robert Z. Orlowski
Special Coverage
Blog
Oct 27, 2024, 17:41
Mike Thompson: Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease
Opinion
Oct 27, 2024, 17:37
Andrea Suarez: Only 25% of cancer patients in clinical trials are asked about side effects they find intolerable
Blog
Oct 27, 2024, 17:31
CML review series with Talha Badar
Blog
Oct 27, 2024, 17:16
Aisling Barrett: Translational analysis of the ANIMATE study at ISHL 13
Blog
Oct 27, 2024, 17:11
AACR Scholars in Training Award - KidneyCAN
Blog
Oct 27, 2024, 17:07
Marking 10 Years of Mentoring for Equality - National Mentoring Day
Blog
Oct 27, 2024, 16:57
Harold J. Burstein: 71% of US counties either lack an oncologist or lack an open cancer trials
Blog
Oct 27, 2024, 16:50
Epigenetic hallmarks affected in human cancer, suggested by Gianluca Sbardella
Blog
Oct 27, 2024, 16:43
Neeraj Agarwal: Premier symposium on Transformation in Cancer Care Delivery
Blog
Oct 27, 2024, 14:33
Andrew Pannu: Competitive landscape for targeted therapies in oncology
Blog
Oct 27, 2024, 14:27
Olubukola Ayodele: Privileged to present an online talk on breast cancer awareness at the College of Medicine, University of Lagos
Blog
Oct 27, 2024, 14:23
Gregg Margolis: Three things to read about health policy